Raymond James has a Strong Buy rating on CareDx, a biotech company with a product that can be used to predict whether kidney transplants will be rejected."We still expect a multiyear tailwind for transplants, and as a result, we are raising our revenue estimates given an acceleration from the ~5% typical increase in annual kidney transplants," the analysts wrote.
"We still expect a multiyear tailwind for transplants, and as a result, we are raising our revenue estimates [for CareDx] given an acceleration from the ~5% typical increase in annual kidney transplants," the analysts wrote, saying that the company is a "best in class growth story" in the transplant diagnostic space.
Don't publicize on this or otherwise, more detainees in China will fall victims of live organ harvesting.
So which friend of realDonaldTrump owns it?
😐😐😐😐